-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncodesign Precision Medicine Swings to H1 2026 Net Loss of EUR 2.04 Million

PUBT·10/22/2026 16:12:42
Listen to the news
Oncodesign Precision Medicine Swings to H1 2026 Net Loss of EUR 2.04 Million
  • Oncodesign Precision Medicine swung to a first-half 2026 net loss of EUR 2.04 million from a EUR 9.85 million year-earlier profit.
  • Revenue fell 21% to EUR 110,000 from a year earlier.
  • Consumed purchases dropped 52% to EUR 1.08 million, while personnel expenses declined 42% to EUR 870,000.
  • Cash totaled EUR 2.86 million at June 30; continued operations remain dependent on securing additional funding.
  • Michael J. Fox Foundation funding supports OPM-201 development toward a phase 1b Parkinson’s trial in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncodesign Precision Medicine SA published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.